ANALYSIS OF CHANGES IN THE SERUM LEVEL NT-proBNP AFTER ACE INHIBITORS THERAPY IN PATIENTS WITH HEART FAILURE

Halla Hisan Hartoto, Bambang Subakti Zulkarnain, Muhammad Aminuddin

= http://dx.doi.org/10.20473/fmi.v52i3.5451
Abstract views = 842 times | downloads = 791 times

Abstract


BNP secreted by left ventricle as response to wall stress in patient with heart failure. Elevated concentration of NT-pro-BNP correlate with severity of heart failure across all stages of the condition and left ventricle ejection fraction in patient. Several clinical trials have demonstrated that neurohormonal modulation on the RAAS decreases NT-proBNP level and results in favorable outcomes. One of the drug used for blocked RAAS system is ACE inhibitor, decrease of NT-proBNP level show response to therapy include therapy with ACE inhibitors. To analize changes in the levels serum NT-proBNP levels after ace inhibitor therapy in patients with heart failure and monitoring creatinine serum. This study was a observational, prospective, non-randomized trial involving patient age 21-75 years, with NYHA class II-III HF, using ACE inhibitor therapy plus other therapy maximum 3 months before study without ARB or beta blocker. We compared serum NT-pro-BNP and creatinin serum parameters before and after two months treatment with ACE inhibitor. This study conducted in cardiovascular ambulatory patient dr. Soetomo hospital Surabaya. Between August-November 2015, 13 patient (38-63 years, 6 woman, 7 men) include in this study. The mean baseline level of NT-proBNP is 2166.92±1236.73 pg/ml, and creatinin serum 1.023±0.601 mg/dL. The NT-pro-BNP were significantly decreased after two months of treatment with ACE inhibitors 1508.23±651 pg/mL (p=0.025), there were no significant differences creatinin serum between two groups 0.951±0.0365 mg/dL (p=0.111). The results demonstrated the benefits of ACE inhibitor on the neurohormonal profile in patients with HF. If necessary we could measure NT-proBNP level to support prognosis data and monitoring effectivity therapy especially ACE inhibitor which had antiremodelling effect towards patients with HF.

Keywords


Natriuretic peptide; NT-proBNP; heart failure; angiotensin-converting enzyme inhibitors

Full Text:

PDF

References


deBoer RA and van Veldhuisen DJ (2008). ACE-inhibitors, Beta-blockers or the combination in heart failure: is it just an A-B-C?. Cardiovasc Drugs Ther 22, 261–263

Januzzi JL, Rehman SU, Mohammed AA, Bhardwaj A, Barajas L, Barajas J, Kim HN, Baggish AL, Weiner RB, Chen-Tournoux A, Marshall JE (2011). Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. Journal of the American College of Cardiology 58, 1881-1889

Kim HN and Januzzi JL (2011). Natriuretic peptide testing in heart failure. Circulation 123, 2015-2019

Loscalzo J (2010). Harrison’s: Cardiovascular Medicine, New York, McGraw-Hill Comp, p 178-197

Morrow DA (2006). Cardiovascular Biomarkers: Pathophysiology And Disease Management, New Jersey, Humana Press Inc, p 345-370

Mueller T, Gegenhuber A, Dieplinger B, Poelz W, Haltmayer M (2004). Long-term stability of endogenous B-type natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP) in frozen plasma samples. Clin Chem Lab Med 42, 942-944

Savioli NF, Magalhães HM, Batlouni M, Piegas LS (2009). ACE inhibitors and plasma B-type natriuretic peptide levels in elderly patients with heart failure. Arquivos Brasileiros de Cardiologia 92, 349-356

Srisawasdi P, Vanavanan S, Charoenpanichkit C, Kroll MH (2010). The effect of renal dysfunction on BNP, NT-proBNP, and their ratio. American Journal of Clinical Pathology 133, 14-23

Tsutamoto T, Sakai H, Ishikawa C, Fujii M, Tanaka T, Yamamoto T, Takashima H, Ohnishi M, Wada A, Horie M (2007). Direct comparison of transcardiac difference between brain natriuretic peptide (BNP) and N-terminal pro-BNP in patients with chronic heart failure. European Journal of Heart Failure 9, 667-673

Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Matsui T, Kinoshita M (2001). Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. Journal of the American College of Cardiology 37, 1228–1233

Tsutamoto T, Wada A, Sakai H, Ishikawa C, Tanaka T, Hayashi M, Fujii M, Yamamoto T, Dohke T, Ohnishi M, Takashima H, Kinoshita M, Horie M (2006). Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. Journal of the American College of Cardiology 47, 582-586


Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 Halla Hisan Hartoto, Bambang Subakti Zulkarnain, Muhammad Aminuddin

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Indexed By

View My Stats

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.